JP2016511407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511407A5 JP2016511407A5 JP2015560715A JP2015560715A JP2016511407A5 JP 2016511407 A5 JP2016511407 A5 JP 2016511407A5 JP 2015560715 A JP2015560715 A JP 2015560715A JP 2015560715 A JP2015560715 A JP 2015560715A JP 2016511407 A5 JP2016511407 A5 JP 2016511407A5
- Authority
- JP
- Japan
- Prior art keywords
- tag
- subject
- concentration ratio
- sample
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002632 lipids Chemical class 0.000 claims 45
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 43
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 43
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims 36
- 238000000034 method Methods 0.000 claims 35
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims 34
- 229940106189 ceramide Drugs 0.000 claims 34
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims 34
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims 34
- 208000024172 Cardiovascular disease Diseases 0.000 claims 31
- 201000001320 Atherosclerosis Diseases 0.000 claims 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 6
- 108090000790 Enzymes Proteins 0.000 claims 5
- 102000004190 Enzymes Human genes 0.000 claims 5
- VODZWWMEJITOND-NXCSZAMKSA-N N-octadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC VODZWWMEJITOND-NXCSZAMKSA-N 0.000 claims 5
- 108010028554 LDL Cholesterol Proteins 0.000 claims 4
- KEPQASGDXIEOIL-UHFFFAOYSA-N (2S,3R)-N-(docosanoate)-1,3-dihydroxy-2-amino-octadeca-4-(E)-ene Natural products CCCCCCCCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC KEPQASGDXIEOIL-UHFFFAOYSA-N 0.000 claims 3
- 102000030169 Apolipoprotein C-III Human genes 0.000 claims 3
- 108010056301 Apolipoprotein C-III Proteins 0.000 claims 3
- 108010023302 HDL Cholesterol Proteins 0.000 claims 3
- KEPQASGDXIEOIL-GLQCRSEXSA-N N-docosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC KEPQASGDXIEOIL-GLQCRSEXSA-N 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 238000004949 mass spectrometry Methods 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 239000013589 supplement Substances 0.000 claims 3
- 101710095342 Apolipoprotein B Proteins 0.000 claims 2
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 2
- 102000018616 Apolipoproteins B Human genes 0.000 claims 2
- 108010027006 Apolipoproteins B Proteins 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 2
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 2
- YDNKGFDKKRUKPY-TURZORIXSA-N N-hexadecanoylsphingosine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC YDNKGFDKKRUKPY-TURZORIXSA-N 0.000 claims 2
- XWBWIAOWSABHFI-NUKVNZTCSA-N N-icosanoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)\C=C\CCCCCCCCCCCCC XWBWIAOWSABHFI-NUKVNZTCSA-N 0.000 claims 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- YIGARKIIFOHVPF-YMBRMJIUSA-N 1-(beta-D-galactosyl)-N-behenoylsphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YIGARKIIFOHVPF-YMBRMJIUSA-N 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 108010071619 Apolipoproteins Proteins 0.000 claims 1
- 102000007592 Apolipoproteins Human genes 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010000891 acute myocardial infarction Diseases 0.000 claims 1
- JUZJEIYRVNAPCT-AKLUEIBQSA-N alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer(d18:1/24:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 JUZJEIYRVNAPCT-AKLUEIBQSA-N 0.000 claims 1
- 239000012491 analyte Substances 0.000 claims 1
- 230000003143 atherosclerotic effect Effects 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 238000001506 fluorescence spectroscopy Methods 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 238000005305 interferometry Methods 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 239000013642 negative control Substances 0.000 claims 1
- 208000030613 peripheral artery disease Diseases 0.000 claims 1
- 230000010287 polarization Effects 0.000 claims 1
- 239000013641 positive control Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000012089 stop solution Substances 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 230000001502 supplementing effect Effects 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 claims 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775445P | 2013-03-08 | 2013-03-08 | |
| US61/775,445 | 2013-03-08 | ||
| PCT/EP2014/054499 WO2014135696A1 (en) | 2013-03-08 | 2014-03-07 | Non-high density lipoprotein derived cvd markers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016511407A JP2016511407A (ja) | 2016-04-14 |
| JP2016511407A5 true JP2016511407A5 (https=) | 2017-04-13 |
Family
ID=50236206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560715A Pending JP2016511407A (ja) | 2013-03-08 | 2014-03-07 | 非高比重リポタンパク質由来ｃｖｄマーカー |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20160018423A1 (https=) |
| EP (1) | EP2965092A1 (https=) |
| JP (1) | JP2016511407A (https=) |
| CN (1) | CN105008931A (https=) |
| CA (1) | CA2903946A1 (https=) |
| WO (1) | WO2014135696A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9347960B2 (en) * | 2014-06-16 | 2016-05-24 | Zora Biosciences, Oy | Ceramides and their use in diagnosing CVD |
| CA2973116C (en) * | 2015-01-09 | 2023-08-15 | Global Genomics Group, LLC | Blood based biomarkers for diagnosing atherosclerotic coronary artery disease |
| CN105748469B (zh) * | 2016-02-24 | 2019-07-23 | 长沙佰顺生物科技有限公司 | 一种安塞曲匹辛伐他汀药物组合物 |
| WO2019119049A1 (en) * | 2017-12-20 | 2019-06-27 | Baker Heart and Diabetes Institute | Method of predicting drug therapeutic responder status and methods of treatment |
| CA3122035A1 (en) * | 2018-12-06 | 2020-06-11 | Zora Biosciences Oy | Biomarkers for cardiovascular events |
| CN112630344B (zh) * | 2020-12-08 | 2021-12-14 | 河北医科大学第二医院 | 代谢标志物在脑梗死中的用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101838B2 (en) * | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
| DE19756255C2 (de) * | 1997-12-17 | 1999-11-11 | Heinrich Wieland | Verfahren und Diagnostikprodukt zur Bestimmung von in Lipoprotein enthaltenem Triglycerid |
| JP4062514B2 (ja) * | 2001-01-02 | 2008-03-19 | ザ・クリーブランド・クリニック・ファンデーション | ミエロペルオキシダーゼ、心臓血管疾患についての危険性指示因子 |
| EP1234816B1 (de) * | 2001-02-23 | 2004-06-30 | Biofrontera Pharmaceuticals GmbH | Scyphostatin-Analoga als SMase-Inhibitoren |
| WO2006057081A1 (en) * | 2004-11-24 | 2006-06-01 | Mitsuyo Okazaki | Method for analyzing lipoproteins |
| EP2126589A4 (en) * | 2007-02-22 | 2011-06-08 | Lipomics Technologies Inc | METABOLISM AND DIABETIC SUFFERING AND METHOD OF USE THEREOF |
| AU2010324544A1 (en) * | 2009-11-27 | 2012-06-21 | Baker Idi Heart And Diabetes Institute Holdings Limited | Lipid biomarkers for stable and unstable heart disease |
| CN103154742B (zh) * | 2010-06-20 | 2017-11-21 | 佐拉生物科学公司 | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 |
| ES2552371T3 (es) * | 2012-05-25 | 2015-11-27 | Zora Biosciences Oy | Biomarcadores sensibles, eficaces e inocuos, para la inhibición de la Proproteína Convertasa Subtilisina/Kexina de tipo 9 (PCSK9) |
-
2014
- 2014-03-07 CA CA2903946A patent/CA2903946A1/en not_active Abandoned
- 2014-03-07 EP EP14708309.1A patent/EP2965092A1/en not_active Withdrawn
- 2014-03-07 US US14/773,095 patent/US20160018423A1/en not_active Abandoned
- 2014-03-07 WO PCT/EP2014/054499 patent/WO2014135696A1/en not_active Ceased
- 2014-03-07 JP JP2015560715A patent/JP2016511407A/ja active Pending
- 2014-03-07 CN CN201480012751.3A patent/CN105008931A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marcovina et al. | Lipoprotein (a) measurements for clinical application | |
| D’Alessandro et al. | Biological and clinical factors contributing to the metabolic heterogeneity of hospitalized patients with and without COVID-19 | |
| CN103154742B (zh) | 用于鉴定高风险冠状动脉疾病患者的脂质组学标志 | |
| Bank et al. | The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease | |
| JP6388284B2 (ja) | スタチン治療を受けている冠動脈疾患患者の心血管転帰を予測するためのリピドミックバイオマーカー | |
| CN103917876B (zh) | 用于预测未接受他汀药物治疗的冠状动脉疾病患者的心血管后果的脂质组学生物标志 | |
| JP2016511407A5 (https=) | ||
| Dinkelaar et al. | Global coagulation tests: their applicability for measuring direct factor Xa-and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate | |
| CN106461685B (zh) | 神经酰胺及其在诊断cvd中的应用 | |
| EP3425406B1 (en) | Method for measuring lipoprotein's capacity to accept cholesterol and reagent kit | |
| Rossouw et al. | Comparability of 11 different equations for estimating LDL cholesterol on different analysers | |
| Frantzi et al. | Clinical proteomics: closing the gap from discovery to implementation | |
| Janckila et al. | Naphthol‐ASBI phosphate as a preferred substrate for tartrate‐resistant acid phosphatase isoform 5b | |
| Meier et al. | Activation of the tryptophan/serotonin pathway is associated with severity and predicts outcomes in pneumonia: results of a long-term cohort study | |
| Karagiannidis et al. | Correlation of the severity of coronary artery disease with patients' metabolic profile-rationale, design and baseline patient characteristics of the CorLipid trial | |
| JP2015526696A5 (https=) | ||
| Wang et al. | Proteome-based identification of apolipoprotein A-IV as an early diagnostic biomarker in liver fibrosis | |
| Lavatelli et al. | Biochemical markers in early diagnosis and management of systemic amyloidoses | |
| Panis et al. | Short infusion of paclitaxel imbalances plasmatic lipid metabolism and correlates with cardiac markers of acute damage in patients with breast cancer | |
| US9347959B2 (en) | Oxidative biomarkers in predicting risk of stroke, transient ischemic attack (TIA) and peripheral arterial disease (PAD) | |
| Sato et al. | Cell-free, high-density lipoprotein–specific phospholipid efflux assay predicts incident cardiovascular disease | |
| Yassine et al. | The application of multiple reaction monitoring and multi-analyte profiling to HDL proteins | |
| Charlton-Menys et al. | Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS) | |
| Masana et al. | Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy | |
| Garcia-Ovejero et al. | Untargeted blood serum proteomics identifies novel proteins related to neurological recovery after human spinal cord injury |